Bobby has served as President and CEO of Tarsus Pharmaceuticals since co-founding the company in 2017. In that time, Tarsus has established a leading team and culture, and completed successful fundraising efforts through an IPO and global partnerships. Tarsus continues to advance its pipeline into clinical studies, including its lead product, TP-03, which is now in Phase 3 clinical trials and commercial planning.
Bobby also serves on the board and is Co-Chairman of Vibrato Medical, a medical device company developing a wearable treatment for peripheral arterial diseases, which has received NIH grant awards and generated first-in-human proof of concept clinical data. Previously, he was President and CMO of Metavention, a medical device company developing an interventional treatment for metabolic diseases, from inception through proof of concept clinical trials as well as Series A through Series C fundraising.
Bobby began his biotechnology career at Versant Ventures and Third Rock Ventures, where he was an investor and board observer in numerous life sciences companies. He also served on the board of the nonprofit organization Octane.
He trained as a physician scientist, completing his residency in internal medicine and serving as an attending hospitalist at Brigham and Women’s Hospital. He received an MD from Harvard Medical School (Harvard-MIT Heath Sciences and Technology), a PhD in chemistry from Oxford University as a Rhodes Scholar, and a BA in physics from Rice University. He is also an author of numerous patents and peer-reviewed publications.
What is Bobak R. Azamian's net worth?
The estimated net worth of Bobak R. Azamian is at least $13.95 million as of March 15th, 2023. Dr. Azamian owns 1,080,536 shares of Tarsus Pharmaceuticals stock worth more than $13,949,720 as of March 21st. This net worth estimate does not reflect any other assets that Dr. Azamian may own. Learn More about Bobak R. Azamian's net worth.
What is Bobak R. Azamian's salary?
As the CEO of Tarsus Pharmaceuticals, Inc., Dr. Azamian earned a total compensation package of $6,870,723.00 in 2021. Dr. Azamian earned a salary of $550,000.00, a bonus of $269,500.00, options awards of $6,029,589.00, and other compensation of $21,634.00. Learn More on Bobak R. Azamian's salary.
How do I contact Bobak R. Azamian?
Has Bobak R. Azamian been buying or selling shares of Tarsus Pharmaceuticals?
Within the last three months, Bobak R. Azamian has sold $590,776.05 in shares of Tarsus Pharmaceuticals stock. Most recently, Bobak R. Azamian sold 8,000 shares of the business's stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $13.79, for a transaction totalling $110,320.00. Following the completion of the sale, the chief executive officer now directly owns 1,080,536 shares of the company's stock, valued at $14,900,591.44. Learn More on Bobak R. Azamian's trading history.
Who are Tarsus Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Tarsus Pharmaceuticals?
During the last year, Tarsus Pharmaceuticals insiders bought shares 2 times. They purchased a total of 118,400 shares worth more than $1,646,608.00. During the last year, insiders at the sold shares 33 times. They sold a total of 200,369 shares worth more than $3,037,765.74. The most recent insider tranaction occured on March, 16th when VP Mark J Holdbrook sold 187 shares worth more than $2,511.41. Insiders at Tarsus Pharmaceuticals own 24.7% of the company.
Learn More about insider trades at Tarsus Pharmaceuticals. Information on this page was last updated on 3/16/2023.
